Evolent Health/$EVH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Evolent Health
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.
Ticker
$EVH
Sector
Primary listing
NYSE
Industry
Health Care Technology
Headquarters
Employees
4,500
Website
Evolent Health Metrics
BasicAdvanced
$1.1B
-
-$1.22
1.04
-
Price and volume
Market cap
$1.1B
Beta
1.04
52-week high
$33.63
52-week low
$7.06
Average daily volume
3.2M
Financial strength
Current ratio
0.985
Quick ratio
0.916
Long term debt to equity
58.748
Total debt to equity
77.085
Interest coverage (TTM)
-0.06%
Profitability
EBITDA (TTM)
84.434
Gross margin (TTM)
15.25%
Net profit margin (TTM)
-4.54%
Operating margin (TTM)
-0.13%
Effective tax rate (TTM)
0.46%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
-0.04%
Return on equity (TTM)
-9.24%
Valuation
Price to revenue (TTM)
0.475
Price to book
1.23
Price to tangible book (TTM)
-1.22
Price to free cash flow (TTM)
-28.007
Free cash flow yield (TTM)
-3.57%
Free cash flow per share (TTM)
-0.353
Growth
Revenue change (TTM)
10.24%
Earnings per share change (TTM)
-2.38%
3-year revenue growth (CAGR)
34.31%
3-year earnings per share growth (CAGR)
47.63%
10-year earnings per share growth (CAGR)
-21.90%
What the Analysts think about Evolent Health
Analyst ratings (Buy, Hold, Sell) for Evolent Health stock.
Bulls say / Bears say
Evolent Health has reaffirmed its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and full-year guidance of $135M-$165M, citing below-expected oncology cost trends through May 2025. CFO John Johnson expressed confidence in meeting or exceeding Q2 expectations, suggesting performance could reach the upper half of the guidance range if current trends persist. (stocktitan.net)
The company secured a Commitment Letter with Ares Management Credit funds for potential additional non-dilutive financing to address 2025 Convertible Notes and support working capital needs, indicating proactive financial management. (stocktitan.net)
CEO Seth Blackley highlighted a significant increase in their 2026 revenue bookings forecast due to accelerating business development activities, suggesting strong future growth prospects. (stocktitan.net)
Evolent Health reported a net loss of $72.3 million ($0.63 per share) in Q1 2025, compared to a loss of $25.2 million ($0.22 per share) in the prior year, indicating worsening financial performance. (stocktitan.net)
The company's revenue for Q1 2025 was $483.6 million, down from $639.7 million in Q1 2024, reflecting a significant decline in top-line growth. (stocktitan.net)
Analysts have lowered their price targets for Evolent Health, with Barclays cutting its price objective from $39.00 to $19.00 and Stephens decreasing its target price from $38.00 to $16.00, indicating reduced confidence in the company's stock performance. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.
Evolent Health Financial Performance
Revenues and expenses
Evolent Health Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Evolent Health stock?
Evolent Health (EVH) has a market cap of $1.1B as of August 01, 2025.
What is the P/E ratio for Evolent Health stock?
The price to earnings (P/E) ratio for Evolent Health (EVH) stock is 0 as of August 01, 2025.
Does Evolent Health stock pay dividends?
No, Evolent Health (EVH) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Evolent Health dividend payment date?
Evolent Health (EVH) stock does not pay dividends to its shareholders.
What is the beta indicator for Evolent Health?
Evolent Health (EVH) has a beta rating of 1.04. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.